Radiation oncology has recently seen tremendous technical advances, resulting in increasing cancer cures. However, malignant neoplasias are systemic diseases and may be lethal even with an excellent tumor local control. Immune therapy has grown to a mature approach in oncology, delivering results impossible only a few years ago. Treatment-limiting mechanisms such as the immune suppressive tumor microenvironment are now to a large extent deciphered, allowing for pharmacological intervention. Interestingly, radiation-based treatment effects have been shown to depend to a large degree on the immune system. Applying the recent advances in radiation therapy in conjunction with immune therapy can be a turning point towards the long-standing aim o...
Approximately one-half of patients with newly diagnosed cancer and many patients with persistent or ...
Approximately one-half of patients with newly diagnosed cancer and many patients with persistent or ...
Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the developme...
Radiation oncology has recently seen tremendous technical advances, resulting in increasing cancer c...
There is a very strong biological and pre-clinical rationale for combining radiotherapy with immune ...
Radiotherapy is an important cornerstone in cancer treatment. Ionizing gamma-irradiation is capable ...
There is a very strong biological and pre-clinical rationale for combining radiotherapy with immune ...
There is a very strong biological and pre-clinical rationale for combining radiotherapy with immune ...
There is a very strong biological and pre-clinical rationale for combining radiotherapy with immune ...
There is a very strong biological and pre-clinical rationale for combining radiotherapy with immune ...
The conventional use of radiotherapy is for local tumor control. Radiotherapy of the primary tumor c...
Since its first clinical application, 120 years ago, radiotherapy evolved into a major anti-cancer t...
Radiotherapy (RT) is currently used in more than 50% of cancer patients during the course of their d...
Traditional treatment approaches for advanced malignancies have been associated with limited clinica...
Radiotherapy is an effective treatment modality commonly used in efforts to cure many localised canc...
Approximately one-half of patients with newly diagnosed cancer and many patients with persistent or ...
Approximately one-half of patients with newly diagnosed cancer and many patients with persistent or ...
Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the developme...
Radiation oncology has recently seen tremendous technical advances, resulting in increasing cancer c...
There is a very strong biological and pre-clinical rationale for combining radiotherapy with immune ...
Radiotherapy is an important cornerstone in cancer treatment. Ionizing gamma-irradiation is capable ...
There is a very strong biological and pre-clinical rationale for combining radiotherapy with immune ...
There is a very strong biological and pre-clinical rationale for combining radiotherapy with immune ...
There is a very strong biological and pre-clinical rationale for combining radiotherapy with immune ...
There is a very strong biological and pre-clinical rationale for combining radiotherapy with immune ...
The conventional use of radiotherapy is for local tumor control. Radiotherapy of the primary tumor c...
Since its first clinical application, 120 years ago, radiotherapy evolved into a major anti-cancer t...
Radiotherapy (RT) is currently used in more than 50% of cancer patients during the course of their d...
Traditional treatment approaches for advanced malignancies have been associated with limited clinica...
Radiotherapy is an effective treatment modality commonly used in efforts to cure many localised canc...
Approximately one-half of patients with newly diagnosed cancer and many patients with persistent or ...
Approximately one-half of patients with newly diagnosed cancer and many patients with persistent or ...
Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the developme...